Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Summary

Phase 2 randomized double-blind trial evaluating multiple once-weekly retatrutide dose regimens against placebo for 48 weeks in adults with obesity or overweight without diabetes.

Limitations

Phase 2 sample size and duration limit certainty about rare adverse events, long-term maintenance and clinical outcomes. The trial was industry funded.

Linked peptides

• Retatrutide